Abstract
Objective—To assess short- and long-term efficacy of an inactivated bovine respiratory syncytial virus (BRSV) vaccine administered IM to calves with maternally derived antibodies.
Animals—28 two-week-old calves with neutralizing, maternally derived antibodies against BRSV.
Procedure—For evaluation of short-term efficacy, 6 calves were vaccinated IM at 2 and 6 weeks of age and challenged intranasally and intratracheally along with a matched group of 4 unvaccinated control calves at 10 weeks of age. For evaluation of long-term efficacy, 2 groups of 6 calves each were vaccinated IM at 2, 6, and 18 weeks of age or 14 and 18 weeks of age; these calves were challenged intranasally and intratracheally along with 6 matched unvaccinated control calves at 43 weeks of age. Serum virus neutralizing antibody titer, clinical reactions, and virus shedding in nasal mucus and lung washings were assessed.
Results—None of the vaccination regimens resulted in a significant increase in serum virus neutralizing antibody titer. As judged by virus shedding in nasal mucus and lung washings, vaccinated calves were protected against challenge, compared with unvaccinated control groups. Clinical signs attributable to challenge were coughing (short-term efficacy study) and tachypnea and dyspnea (long-term efficacy study). The severity and incidence of disease were significantly lower in the vaccinated groups, compared with that in the unvaccinated groups.
Conclusions and Clinical Relevance—Through vaccination, it is possible to protect vulnerable calves with maternal antibodies against BRSV infection and reduce respiratory tract disease. (Am J Vet Res 2004;65:417–421)
